No material company-specific news briefings were available for Amgen Inc. in the 30-day period leading to this report's generation date of 19 September 2026. The report was triggered primarily by material institutional position changes identified in recent 13F filings, as detailed below. [Brief - 2026-09-11]
Amgen's trailing twelve-month revenue as of 30 June 2026 stood at $38.10 billion, representing year-over-year growth of 9.53%. Net income for the same period was $8.74 billion, with a net margin of 22.95% and an operating margin of 29.99%. Gross margin was recorded at 47.46%. Earnings per share grew 64.91% year-over-year. The company held $13.99 billion in cash against total debt of $59.30 billion. Market capitalisation was approximately $208.48 billion, with a price-to-earnings ratio of 23.97. [SEC 10-Q - AMGN - 2026-06-30]
Several notable institutional position changes were recorded in recent 13F filings. Citadel added approximately 60% to its existing AMGN position, while AQR Capital nearly doubled its holdings with a 97% addition. Bridgewater increased its position by 48%. Conversely, Millennium reduced its AMGN position by 36%. No insider transactions via Form 4 filings were available in the provided data for this reporting period. [SEC 13F - Citadel - Q2 2026] [SEC 13F - AQR Capital - Q2 2026] [SEC 13F - Bridgewater - Q2 2026] [SEC 13F - Millennium - Q2 2026]
The prevailing macro environment as of the report date shows the 10-year US Treasury yield at 4.94% and the 2-year yield at 4.67%, producing a normal yield curve spread of approximately 27 basis points. [FRED DGS10] [FRED DGS2] These conditions represent the broader fixed-income backdrop against which Amgen's debt profile of $59.30 billion is situated.